Anusha Kalbasi

/in /by


Anusha Kalbasi, M.D.


Office Address:
CHS 57-200A

Affiliations

Assistant Professor, Radiation Oncology
Research Interests

We conduct basic and translational research at the interface of cancer and the immune system, with an emphasis on developing new strategies to treat sarcoma, a rare mesenchymal cancer for which UCLA is a center of excellence. We are also especially interested in approaches to improve the use and safety of radiotherapy in the treatment of sarcoma. Specific research areas include:
(1) Reprogramming myeloid cells in sarcoma to induce anti-tumor immunity
(2) Exploring and leveraging lymph nodes in T cell based therapies for cancer
(3) IL9 receptor signaling in the effector function of tumor-specific T cells
(4) Tumor cell-intrinsic resistance shared across radiotherapy and immunotherapy
(5) Analysis of samples from human clinical trials of immunotherapy and/or radiotherapy

Publications

A selected list of publications:

Xie C, Kim H, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan R, Wang Y, Marks LS, Pantuck AJ, Taille A, Wang G, Mukouyama H, and Zeng G. “A Novel Multiplex Assay Combining Autoantibodies Plus PSA Significantly Improves Classification of Prostate Cancer from Non-malignant Cases.” Journal of Translational Medicine. 2011 Apr 19;9:43.
Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabró L, Chiou M, Tap W, Chmielowski B, Maio M, Ribas A. “CD40 Expression by Melanocytic Lesions and Human Melanoma Cell Lines and Direct CD40 Targeting with the Therapeutic Anti-CD40 Antibody CP-870,893.” Journal of Immunotherapy. 2010 Oct; 33(8):810-816.
Kalbasi A, Shrimali R, Chinnasamy D, Rosenberg SA. “Prevention of apoptosis due to IL-2 withdrawal in lymphocytes retrovirally cotransduced with genes encoding an anti-tumor T cell receptor and an antiapoptotic gene.” Journal of Immunotherapy. 2010 Sep;33(7):672-83.
Kalbasi A, Swisher-McClure S, Mitra N, Sunderland R, Smaldone M, Uzzo RG, Bekelman JE. “Low Rates of Adjuvant Radiation in Non-metastatic Prostate Cancer Patients with High-Risk Pathologic Features.” Cancer. 2014 Oct 1;120(19):3089-96.
Fernandes RS, Gracas Mota L, Kalbasi A, Werner TJ, Alavi A, Cardoso VN, Barros ALB. “99mTcphytate as a diagnostic probe for assessing inflammatory reaction in malignant tumors.” Nuclear Medicine Communication. Nucl Med Commun. 2015 Oct; 36(10);1042-8.
Kalbasi A, Li J, Berman A, Swisher-McClure S, Smaldone M, Small D, Mitra N, Bekelman JE. “Relation of Dose-Escalated Radiation to Overall Survival in Men with Non-metastatic Prostate Cancer.” JAMA Oncology. 2015 Oct; 1(7):897-906.
Kalbasi A, Komar C, Tooker GM, Liu M, Gladney WL, Lee JW, Ben-Josef E, Beatty GL. “Tumorderived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma.” Clinical Cancer Research. 2017 Jan 1;23(1):137-148.